Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Geron Corp GERN

Alternate Symbol(s):  GERNW

Healthcare Biotechnology
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the... see more

Recent & Breaking News (NDAQ:GERN)

Geron to Announce First Quarter 2024 Financial Results on May 2, 2024

Business Wire April 25, 2024

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 18, 2024

Geron to Participate at Upcoming Investor Conferences in April

Business Wire April 3, 2024

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Business Wire March 19, 2024

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Business Wire March 14, 2024

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Business Wire February 28, 2024

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 22, 2024

Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Business Wire February 14, 2024

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 18, 2024

Geron to Participate in the B. Riley Securities Virtual Oncology Conference

Business Wire January 12, 2024

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 21, 2023

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS

Business Wire December 11, 2023

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Business Wire December 6, 2023

Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Business Wire December 4, 2023

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Business Wire November 28, 2023

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 16, 2023

Geron to Participate at Upcoming Investor Conferences in November

Business Wire November 7, 2023

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

Business Wire November 2, 2023

Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results

Business Wire November 2, 2023

Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023

Business Wire October 26, 2023